SpringerLink
Log in

Diagnostic efficacy of [68Ga]Ga-NY104 PET/CT to identify clear cell renal cell carcinoma

  • Short Communication
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

Most clear cell renal cell carcinoma (ccRCC) overexpresses carbonic anhydrase IX (CAIX). [68Ga]Ga-NY104 is a small-molecule PET agent selectively targeting CAIX. This study aims to assess the efficacy of [68Ga]Ga-NY104 PET/CT to identify ccRCC.

Materials and methods

Participants were prospectively recruited in the study (ClinicalTrials.gov: NCT05902377). They were further divided into two groups: group 1, patients with primary renal mass who were scheduled for surgery, group 2, patients with suspected/confirmed metastatic ccRCC. All patients underwent [68Ga]Ga-NY104 PET/CT.

Results

A total of 47 patients (mean age, 58.8 years ± 13.5, 34 men) were recruited, including 20 patients in group 1 and 27 patients in group 2. The patient-level sensitivity, specificity, and accuracy of [68Ga]Ga-NY104 PET scan was 62%, 33%, 58% for group 1 and 95%, 100%, 96% for group 2. [68Ga]Ga-NY104 PET identified additional 26 disease regions in 67% (14/21) of patients that were previously unknown. The tumor uptake was correlated with immunohistochemical staining results.

Conclusions

[68Ga]Ga-NY104 PET/CT has a high diagnostic efficacy for patients with metastatic ccRCC, while it might be of limited value in the diagnosis of primary ccRCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17:245–61.

    Article  CAS  PubMed  Google Scholar 

  2. Courcier J, de la Taille A, Nourieh M, Leguerney I, Lassau N, Ingels A. Carbonic anhydrase IX in renal cell carcinoma, implications for disease management. Int J Mol Sci. 2020;21:7146.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Lawrentschuk N, Lee FT, Jones G, et al. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and 124I-cG250 PET/CT. Urol Oncol. 2011;29:411–20.

    Article  CAS  PubMed  Google Scholar 

  4. Divgi CR, Uzzo RG, Gatsonis C, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013;31:187–94.

    Article  PubMed  Google Scholar 

  5. Kulterer OC, Pfaff S, Wadsak W, et al. A microdosing study with (99m)Tc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell carcinoma patients. J Nucl Med. 2021;62:360–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zhu W, Li X, Zheng G, et al. Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2023;50:3116–25.

    Article  CAS  PubMed  Google Scholar 

  7. Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208–16.

    Article  CAS  PubMed  Google Scholar 

  8. Basile G, Fallara G, Verri P, et al. The role of (99m)Tc-sestamibi single-photon emission computed tomography/computed tomography in the diagnostic pathway for renal masses: a systematic review and meta-analysis. Eur Urol. 2024;85:63–71.

    Article  CAS  PubMed  Google Scholar 

  9. Wang HY, Ding HJ, Chen JH, et al. Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging. 2012;12:464–74.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zhao Y, Wu C, Li W, et al. 2-[(18)F]FDG PET/CT parameters associated with WHO/ISUP grade in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48:570–9.

    Article  PubMed  Google Scholar 

  11. Shuch BM, Pantuck AJ, Bernhard J-C. Results from phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ZIRCON). J Clin Oncol. 2023;41:6.

    Article  Google Scholar 

  12. Oosterwijk E. Carbonic anhydrase expression in kidney and renal cancer: implications for diagnosis and treatment. Subcell Biochem. 2014;75:181–98.

    Article  CAS  PubMed  Google Scholar 

  13. Baniak N, Flood TA, Buchanan M, Dal Cin P, Hirsch MS. Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes. Histopathology. 2020;77:659–66.

    Article  PubMed  Google Scholar 

  14. Muselaers CH, Stillebroer AB, Desar IM, et al. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma. J Nucl Med. 2014;55:242–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was funded in part by National High Level Hospital Clinical Research Funding (2022-PUMCH-B-072, 2022-PUMCH-D-001, 2022-PUMCH-B-010, XH-QN-012 K), National Key Research and Development Program of China (No. 2016YFC0901500), CAMS innovation fund for medical science (No. CIFMS-2021-I2M-1-025, CIFMS-2021-I2M-1-002, CIFMS-2021-I2M-1-003), and National Natural Science Foundation of China (No. 82071967, No. 82202218).

Author information

Author notes

  1. Wenjia Zhu and Guoyang Zheng contributed equally to this work.

Authors and Affiliations

  1. Department of Nuclear Medicine, Bei**g Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Shuaifuyuan, Dongcheng District, Bei**g, 100730, China

    Wenjia Zhu, **nchun Yan, Meixi Liu & Li Huo

  2. Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Shuaifuyuan, Dongcheng District, Bei**g, 100730, China

    Guoyang Zheng & Yushi Zhang

  3. Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Bei**g, 100730, China

    **aoyuan Li, Yuejuan Cheng & Chunmei Bai

Authors
  1. Wenjia Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guoyang Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. **nchun Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meixi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. **aoyuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuejuan Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chunmei Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yushi Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Li Huo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Wenjia Zhu, Guoyang Zheng and **nchun Yan. The first draft of the manuscript was written by Wenjia Zhu. The critical revision of the manuscript was provided by Yushi Zhang and Li Huo. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Yushi Zhang or Li Huo.

Ethics declarations

Ethics approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Peking Union Medical College Hospital (Aug 24, 2021 / ZS-3089).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent to publish

The authors affirm that human research participants provided informed consent for publication of the images and data in this article.

Competing interests

Wenjia Zhu and Li Huo are member of inventors for the patent of [68Ga]Ga-NY104.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 925 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, W., Zheng, G., Yan, X. et al. Diagnostic efficacy of [68Ga]Ga-NY104 PET/CT to identify clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging (2024). https://doi.org/10.1007/s00259-024-06801-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00259-024-06801-y

Keywords

Search

Navigation